《新股消息》傳曠視科技通過上市聆訊
去年底曾有消息指,內地人工智能解決方案供應商曠視科技(Megvii)因被美國列入黑名單未能通過上市聆訊。據《路透》引述消息人士指,近日曠視科技已通過港交所(00388.HK)上市聆訊,有望農曆新年假期後、市場回暖時即啟動招股,預計集資約5億至10億美元。
報道指,曠視科技於去年8月底以同股不同權架構申請在港上市,但至10月即被美國列入貿易黑名單,港交所上市委員會因而要求公司提交額外資料。消息人士指,曠視科技將在近日上載更新後的初步招股資料。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.